Top-Rated StocksTop-RatedNASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free UTHR Stock Alerts $243.27 -4.59 (-1.85%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$236.07▼$249.6850-Day Range$210.76▼$249.5152-Week Range$204.44▼$261.54Volume648,210 shsAverage Volume516,110 shsMarket Capitalization$11.45 billionP/E Ratio12.26Dividend YieldN/APrice Target$294.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside21.0% Upside$294.40 Price TargetShort InterestBearish4.43% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.86Based on 27 Articles This WeekInsider TradingSelling Shares$17.89 M Sold Last QuarterProj. Earnings Growth4.07%From $23.32 to $24.27 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector50th out of 939 stocksPharmaceutical Preparations Industry21st out of 433 stocks 3.5 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $294.40, United Therapeutics has a forecasted upside of 21.0% from its current price of $243.27.Amount of Analyst CoverageUnited Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.43% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in United Therapeutics has recently increased by 64.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.3 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for United Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 14 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat Follows8 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,886,630.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 4.07% in the coming year, from $23.32 to $24.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 12.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.09.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 12.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 250.21.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesMarch 28, 2024 | insidertrades.comMartine A. Rothblatt Sells 15,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockMarch 26, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 15,000 SharesMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 23, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $1,418,700.00 in StockMarch 22, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $3,548,850.00 in StockMarch 27, 2024 | gurufocus.comUnited Therapeutics Corp (UTHR) CEO Martine Rothblatt Sells 30,000 SharesMarch 27, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Up to $237.90March 27, 2024 | finance.yahoo.comUnited Therapeutics' Robust Portfolio Fuels Double-Digit GrowthMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 26, 2024 | finance.yahoo.comUnited Therapeutics Announces the First Comprehensive Review Publication on XenotransplantationMarch 26, 2024 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 15,000 Shares of StockMarch 26, 2024 | americanbankingnews.comStockNews.com Lowers United Therapeutics (NASDAQ:UTHR) to BuyMarch 25, 2024 | finance.yahoo.comInsider Sell: United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells ...March 25, 2024 | investorplace.comThe Bargain Hunter's Portfolio: 7 Smart Stock Buys for the Shrewd InvestorMarch 25, 2024 | markets.businessinsider.comUnited Therapeutics To Repurchase Up To $1 Bln SharesMarch 25, 2024 | finance.yahoo.comUnited Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase ProgramMarch 24, 2024 | americanbankingnews.comPaul A. Mahon Sells 6,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockMarch 21, 2024 | finance.yahoo.comUnited Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells 30,000 SharesMarch 18, 2024 | americanbankingnews.comZacks Research Analysts Increase Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)March 16, 2024 | finance.yahoo.comUTHR Aug 2024 170.000 putMarch 16, 2024 | finance.yahoo.comLiquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | finance.yahoo.comUTHR Apr 2024 210.000 putMarch 13, 2024 | finance.yahoo.comQ4 2023 Liquidia Corp Earnings CallMarch 13, 2024 | investorplace.comThe 3 Most Undervalued Nasdaq Stocks to Buy in March 2024March 11, 2024 | finance.yahoo.comUnited Therapeutics Corp Chairperson & CEO Martine Rothblatt Sells 30,000 SharesMarch 10, 2024 | finance.yahoo.comUnited Therapeutics Corporation's (NASDAQ:UTHR) Stock Is Going Strong: Is the Market Following Fundamentals?March 9, 2024 | finance.yahoo.com12 Most Undervalued Biotech Stocks To Buy According To Hedge FundsSee More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$294.40 High Stock Price Target$330.00 Low Stock Price Target$215.00 Potential Upside/Downside+21.0%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$19.84 Trailing P/E Ratio12.26 Forward P/E Ratio10.43 P/E GrowthN/ANet Income$984.80 million Net Margins42.31% Pretax Margin54.75% Return on Equity17.72% Return on Assets14.47% Debt Debt-to-Equity Ratio0.05 Current Ratio4.41 Quick Ratio4.28 Sales & Book Value Annual Sales$2.33 billion Price / Sales4.92 Cash Flow$22.00 per share Price / Cash Flow11.06 Book Value$127.35 per share Price / Book1.91Miscellaneous Outstanding Shares47,060,000Free Float41,177,000Market Cap$11.45 billion OptionableOptionable Beta0.52 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonSenior Vice President of Product DevelopmentMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsMartine A RothblattSold 15,000 sharesTotal: $3.72 M ($248.33/share)PNC Financial Services Group Inc.Bought 164 shares on 3/22/2024Ownership: 0.006%Martine A RothblattSold 15,000 sharesTotal: $3.56 M ($237.05/share)Paul A MahonSold 6,000 sharesTotal: $1.42 M ($236.45/share)Healthcare of Ontario Pension Plan Trust FundBought 20,000 shares on 3/21/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price target for 2024? 11 equities research analysts have issued twelve-month price targets for United Therapeutics' stock. Their UTHR share price targets range from $215.00 to $330.00. On average, they predict the company's share price to reach $294.40 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2024? United Therapeutics' stock was trading at $219.89 at the beginning of the year. Since then, UTHR stock has increased by 10.6% and is now trading at $243.27. View the best growth stocks for 2024 here. Are investors shorting United Therapeutics? United Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,920,000 shares, an increase of 64.1% from the February 29th total of 1,170,000 shares. Based on an average daily trading volume, of 406,600 shares, the days-to-cover ratio is presently 4.7 days. Approximately 4.4% of the company's shares are short sold. View United Therapeutics' Short Interest. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings data on Wednesday, February, 21st. The biotechnology company reported $4.36 EPS for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The biotechnology company had revenue of $614.70 million for the quarter, compared to analysts' expectations of $575.01 million. United Therapeutics had a trailing twelve-month return on equity of 17.72% and a net margin of 42.31%. The company's revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 EPS. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Inspire Faithward Mid Cap Momentum ETF (GLRY), Formidable Fortress ETF (KONG), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Intelligent - Large Cap Value ETF (AILV). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.95%), Vanguard Group Inc. (9.93%), Wellington Management Group LLP (8.06%), Avoro Capital Advisors LLC (6.08%), Dimensional Fund Advisors LP (1.20%) and Nuveen Asset Management LLC (1.05%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UTHR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.